ReViral: LianBio's Partner ReViral Enters into Acquisition Agreement with Pfizer
SHANGHAI AND PRINCETON, N.J., April 07, 2022 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN) announced today that its partner, ReViral Ltd., is expected to be acquired by Pfizer Inc. (NYSE: PFE). LianBio h...
Read full article »
Reviral is an England-based biopharmaceutical company that develops and commercializes antiviral therapeutics for the treatment of the respiratory syncytial virus.
Read more